The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis

2012 ◽  
Vol 27 (9) ◽  
pp. 1083-1091 ◽  
Author(s):  
Tamara Pringsheim ◽  
Katie Wiltshire ◽  
Lundy Day ◽  
Jonathan Dykeman ◽  
Thomas Steeves ◽  
...  
Keyword(s):  
Systematic Review ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Meta Analysis

The Efficacy and Safety of Pridopidine on Treatment of Huntington's Disease Patients: A Systematic Review and Meta‐Analysis

2021 ◽  
Author(s):  
Moamen Mostafa Asla ◽  
Asmaa Ahmed Nawar ◽  
Alaa Abdelsalam ◽  
Esraa Elsayed ◽  
Marwa Abdelazim Rizk ◽  
...  
Keyword(s):  
Systematic Review ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Meta Analysis ◽  
Efficacy And Safety

scholarly journals Exercise Interventions in Huntington's Disease: An Individual Patient Data Meta‐Analysis

2019 ◽  
Vol 6 (7) ◽  
pp. 567-575
Author(s):  
Rebecca Playle ◽  
Polyxeni Dimitropoulou ◽  
Mark Kelson ◽  
Lori Quinn ◽  
Monica Busse
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Patient Data ◽  
Exercise Interventions

Diffusion imaging studies of Huntington's disease: A meta-analysis

2016 ◽  
Vol 32 ◽  
pp. 94-101 ◽  
Author(s):  
Wanglin Liu ◽  
Jing Yang ◽  
JeanMarc Burgunder ◽  
Bochao Cheng ◽  
Huifang Shang
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Meta Analysis ◽  
Diffusion Imaging ◽  
Imaging Studies

scholarly journals The global prevalence of Huntington's disease: a systematic review and discussion

2016 ◽  
Vol 6 (4) ◽  
pp. 331-343 ◽  
Author(s):  
Sheharyar Sajjad Baig ◽  
Mark Strong ◽  
Oliver WJ Quarrell
Keyword(s):  
Systematic Review ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Global Prevalence

scholarly journals The Prevalence of Juvenile Huntington's Disease: A Review of the Literature and Meta-Analysis

PLoS Currents ◽  
2012 ◽  
Vol 4 ◽  
pp. e4f8606b742ef3 ◽  
Author(s):  
Oliver Quarrell ◽  
Kirsty L O'Donovan ◽  
Oliver Bandmann ◽  
Mark Strong
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Meta Analysis ◽  
Review Of The Literature ◽  
Juvenile Huntington’S Disease

scholarly journals Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2021 ◽  
Vol 12 ◽  
Author(s):  
Shujun Chen ◽  
Tianyu Liang ◽  
Tao Xue ◽  
Shouru Xue ◽  
Qun Xue
Keyword(s):  
Adverse Events ◽  
Randomized Controlled Trials ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Meta Analysis ◽  
Statistical Significance ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Motor Score ◽  
Randomized Controlled

Background: Huntington's disease (HD) is a progressive neurodegenerative disorder. Generally, it is characterized by deficits in cognition, behavior, and movement. Recent studies have shown that pridopidine is a potential and effective drug candidate for the treatment of HD. In the present study, we performed a meta-analysis to evaluate the efficacy and safety of pridopidine in HD.Methods: The MEDLINE, EMBASE, CENTRAL, and Clinicaltrials.gov databases were searched for randomized controlled trials (RCTs) which had that evaluated pridopidine therapy in HD patients.Results: We pooled data from 1,119 patients across four RCTs. Patients in the pridopidine group had a significantly lower Unified Huntington's Disease Rating Scale (UHDRS)-modified Motor Score (mMS) (MD −0.79, 95% CI = −1.46 to −0.11, p = 0.02) than those in the placebo group. Additionally, no differences were observed in the UHDRS-Total Motor Score (TMS) (MD −0.91. 95% CI = −2.03 to 0.21, p = 0.11) or adverse events (RR 1.06, 95% CI = 0.96 to 1.16, p = 0.24) in the pridopidine and placebo groups. In the subgroup analysis, the short-term (≤12 weeks) and long-term (>12 weeks) subgroups exhibited similar efficacy and safety with no statistical significance in TMS, mMS, or adverse events. However, TMS (MD −1.50, 95% CI = −2.87 to −0.12, p = 0.03) and mMS (MD −1.03, 95% CI = −1.87 to −0.19, p = 0.02) were observed to be improved significantly when the dosage of pridopidine ≥90 mg/day. Additionally, pridopidine (≥90 mg/day) increased total adverse events (RR 1.11, 95% CI = 1.00 to 1.22, p = 0.04) compared with placebo. On this basis, we analyzed the incidence of various adverse events when the dosage was ≥90 mg/day. Nonetheless, these results were within the acceptable threshold, although patients developed symptoms, such as nasopharyngitis and insomnia.Conclusion: Pridopidine improved mMS and had no statistical significance in association with TMS or adverse events. Pridopidine (≥90 mg/day) improved TMS and mMS but increased adverse events, such as nasopharyngitis and insomnia. More RCTs were expected to assess pridopidine in HD.

Sign in / Sign up

Export Citation Format

Share Document